Healthcare / Diagnostics & ResearchSES
$0.02
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $983114.00 · quality 61.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
61/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$26M
P/E
N/A
•EV/EBITDA
6.7x
↓ROE
12.6%
↑Gross Margin
94.0%
↑Debt/Equity
1.11
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+23.1%
FCF CAGR
+72.5%
FCF margin
3.4%
FCF / Net income
0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $35.2M · net income $2.0M · FCF $1.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $35.2M | $35.2M | $28.9M | $23.6M | $18.9M |
| Net Income | $2.0M | $2.0M | $645718.00 | $1.9M | $2.2M |
| EBITDA | $5.7M | $5.7M | $3.7M | $3.5M | $3.5M |
| EPS | — | — | 0.00 | 0.00 | 0.00 |
| Gross Margin | 94.0% | 94.0% | 92.9% | 92.9% | 92.1% |
| Operating Margin | 0.9% | 0.9% | 1.2% | 1.6% | 3.7% |
| Net Margin | 5.7% | 5.7% | 2.2% | 8.1% | 11.6% |
| Balance Sheet | |||||
| Debt/Equity | 1.11 | 1.11 | 1.48 | 0.71 | 0.67 |
| Current Ratio | 2.10 | 2.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.2M | $1.2M | $675268.00 | $983114.00 | $234080.00 |
| Returns | |||||
| ROE | 12.6% | 12.6% | 4.5% | 14.5% | 20.0% |
| Valuation | |||||
| P/E | — | — | 12.64 | 7.65 | 5.50 |
| EV/EBITDA | 6.66 | 6.66 | 6.99 | 5.54 | 3.74 |
| P/B | 1.62 | 1.62 | 0.89 | 1.11 | 1.13 |
| Growth & Yield | |||||
| Revenue Growth | 21.8% | 21.8% | 22.5% | 25.0% | — |
| EPS Growth | — | — | -48.8% | -15.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+91.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.00 → n/d
Residual
+91.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.